What is the price target for LEU in 2026?
Wall Street research analysts covering Centrus Energy Corp. (LEU) establish consensus 12-month price targets averaging around $217.50 per share. Individual institutional projections span from a conservative low estimate of $104.00 up to an optimistic high bull-case peak reaching $295.00 to $357.00 per share. These forward-looking valuations are supported by rising nuclear fuel enrichment demand, domestic high-assay low-enriched uranium production initiatives, and long-term utility supply contract milestones evaluated by energy sector analysts.
Related FAQs
Centrus Energy Corp. (LEU) operates as a critical supplier of nuclear fuel and enriched uranium components for the commercial nuclear power industry.
Centrus Energy Corp. (trading under the ticker symbol LEU on the NYSE) experienced dynamic market activity driven by shifting sentiment in the nuclear energy sector and quarterly financial performance.
Centrus Energy, trading under the ticker LEU, carries a consensus rating of Buy from analysts tracking the nuclear fuel cycle and clean energy infrastructure sectors.
Investing in nuclear energy has garnered intense institutional interest, driven by surging global demand for clean, reliable baseload electricity required to power energy-intensive artificial intelligence data centers and industrial decarbonization i...
Centrus Energy, trading under the ticker LEU, is a pure-play nuclear fuel stock specializing in the supply of low-enriched uranium and advanced high-assay low-enriched uranium for commercial nuclear power reactors.
Centrus Energy Corp, trading under the ticker LEU, commands fair value expectations that fluctuate dynamically based on geopolitical shifts in nuclear fuel supply chains, government funding for domestic high-assay low-enriched uranium production, and...
Centrus Energy Corp. operates within the nuclear fuel and uranium enrichment sector, carrying specific operational and geopolitical risk factors.
Centrus Energy operates as a profitably structured enterprise, consistently generating positive net income, robust multi-million dollar revenues, and healthy gross margins supported by a massive multi-year customer order backlog.
Yes, LifeStance Health Group (trading under the ticker LFST) has regularly been evaluated and recommended by Wall Street equity research analysts and healthcare investment institutions.
Choosing between investing in physical uranium (via specialized funds or trusts) versus uranium mining stocks involves weighing direct commodity price exposure against operational corporate leverage.
Equity research analysts tracking Centrus Energy Corp., trading under the ticker symbol LEU, highlight its critical position as a Western supplier of nuclear fuel and specialized uranium enrichment.
Centrus Energy Corp. (LEU) operates with a trailing price-to-earnings ratio hovering around 51.9 to 57.